Neurology:芬戈莫德治疗导致的进行性多灶性白质脑病风险极低

2018-04-20 zhangfan MedSci原创

研究认为,对于未接受过那他珠单抗治疗的患者,接受芬戈莫德导致的进行性多灶性白质脑病风险极低,每1000患者的发病率为0.069,每100000患者年发病3.12例

近日研究人员就15名接受芬戈莫德治疗后出现进行性多灶性白质脑病(PML)患者的特征进行描述,对该不良事件风险进行评估。

研究人员考察了截止2017年8月31日诺华公司相关药物安全性数据,依据先前诊断标准对PML病情进行评估,考察所有接受芬戈莫德治疗患者的进行性多灶性白质脑病发病率。

研究发现,15名接受非芬戈莫德+那他珠单抗联合治疗的患者,在6个月前发生PML,其中女性11人,平均年龄53岁。14名患者接受了2年以上的芬戈莫德治疗,2名患者药物记录复杂。2名患者接受那他珠单抗治疗,其中1名接受那他珠单抗治疗患者在最后1次用药3年零9个月后诊断为PML,另1名患者在接受4年6个月的芬戈莫德治疗后终止,转而接受那他珠单抗治疗并在治疗后3个月发展为PML。14名患者的淋巴细胞绝对计数资料可获得,但未发生持续性4级淋巴细胞减少(≤200细胞/μL)。

研究认为,对于未接受过那他珠单抗治疗的患者,接受芬戈莫德导致的进行性多灶性白质脑病风险极低,每1000患者的发病率为0.069,每100000患者年发病3.12例。
芬戈莫德相关的拓展阅读:

原始出处:

Joseph R. Berger et al. Progressive multifocal leukoencephalopathy after fingolimod treatment. Neurology. April 18,2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1981199, encodeId=67ea19811992d, content=<a href='/topic/show?id=ccaf4332947' target=_blank style='color:#2F92EE;'>#多灶性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43329, encryptionId=ccaf4332947, topicName=多灶性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a885259, createdName=yourmama, createdTime=Thu Oct 18 02:20:00 CST 2018, time=2018-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700886, encodeId=5c151e0088609, content=<a href='/topic/show?id=5bc99439474' target=_blank style='color:#2F92EE;'>#进行性多灶性白质脑病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94394, encryptionId=5bc99439474, topicName=进行性多灶性白质脑病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c15930270246, createdName=xuyu, createdTime=Mon Dec 17 06:20:00 CST 2018, time=2018-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765715, encodeId=f32b1e65715ae, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Dec 14 15:20:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000398, encodeId=b341200039878, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Oct 10 09:20:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666416, encodeId=9eba1666416ff, content=<a href='/topic/show?id=55c6849451c' target=_blank style='color:#2F92EE;'>#脑病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84945, encryptionId=55c6849451c, topicName=脑病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db0126060584, createdName=showtest, createdTime=Fri Jan 25 23:20:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976609, encodeId=31c019e660932, content=<a href='/topic/show?id=acd4943925f' target=_blank style='color:#2F92EE;'>#进行性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94392, encryptionId=acd4943925f, topicName=进行性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=869698, createdName=ligang4439, createdTime=Sun Dec 09 20:20:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620952, encodeId=e3e2162095247, content=<a href='/topic/show?id=92008691089' target=_blank style='color:#2F92EE;'>#芬戈莫德#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86910, encryptionId=92008691089, topicName=芬戈莫德)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=311d20178410, createdName=shenxlcyp, createdTime=Sun Apr 22 04:20:00 CST 2018, time=2018-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307603, encodeId=237230e6030c, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Fri Apr 20 13:45:36 CST 2018, time=2018-04-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1981199, encodeId=67ea19811992d, content=<a href='/topic/show?id=ccaf4332947' target=_blank style='color:#2F92EE;'>#多灶性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43329, encryptionId=ccaf4332947, topicName=多灶性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a885259, createdName=yourmama, createdTime=Thu Oct 18 02:20:00 CST 2018, time=2018-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700886, encodeId=5c151e0088609, content=<a href='/topic/show?id=5bc99439474' target=_blank style='color:#2F92EE;'>#进行性多灶性白质脑病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94394, encryptionId=5bc99439474, topicName=进行性多灶性白质脑病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c15930270246, createdName=xuyu, createdTime=Mon Dec 17 06:20:00 CST 2018, time=2018-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765715, encodeId=f32b1e65715ae, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Dec 14 15:20:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000398, encodeId=b341200039878, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Oct 10 09:20:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666416, encodeId=9eba1666416ff, content=<a href='/topic/show?id=55c6849451c' target=_blank style='color:#2F92EE;'>#脑病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84945, encryptionId=55c6849451c, topicName=脑病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db0126060584, createdName=showtest, createdTime=Fri Jan 25 23:20:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976609, encodeId=31c019e660932, content=<a href='/topic/show?id=acd4943925f' target=_blank style='color:#2F92EE;'>#进行性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94392, encryptionId=acd4943925f, topicName=进行性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=869698, createdName=ligang4439, createdTime=Sun Dec 09 20:20:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620952, encodeId=e3e2162095247, content=<a href='/topic/show?id=92008691089' target=_blank style='color:#2F92EE;'>#芬戈莫德#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86910, encryptionId=92008691089, topicName=芬戈莫德)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=311d20178410, createdName=shenxlcyp, createdTime=Sun Apr 22 04:20:00 CST 2018, time=2018-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307603, encodeId=237230e6030c, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Fri Apr 20 13:45:36 CST 2018, time=2018-04-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1981199, encodeId=67ea19811992d, content=<a href='/topic/show?id=ccaf4332947' target=_blank style='color:#2F92EE;'>#多灶性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43329, encryptionId=ccaf4332947, topicName=多灶性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a885259, createdName=yourmama, createdTime=Thu Oct 18 02:20:00 CST 2018, time=2018-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700886, encodeId=5c151e0088609, content=<a href='/topic/show?id=5bc99439474' target=_blank style='color:#2F92EE;'>#进行性多灶性白质脑病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94394, encryptionId=5bc99439474, topicName=进行性多灶性白质脑病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c15930270246, createdName=xuyu, createdTime=Mon Dec 17 06:20:00 CST 2018, time=2018-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765715, encodeId=f32b1e65715ae, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Dec 14 15:20:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000398, encodeId=b341200039878, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Oct 10 09:20:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666416, encodeId=9eba1666416ff, content=<a href='/topic/show?id=55c6849451c' target=_blank style='color:#2F92EE;'>#脑病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84945, encryptionId=55c6849451c, topicName=脑病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db0126060584, createdName=showtest, createdTime=Fri Jan 25 23:20:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976609, encodeId=31c019e660932, content=<a href='/topic/show?id=acd4943925f' target=_blank style='color:#2F92EE;'>#进行性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94392, encryptionId=acd4943925f, topicName=进行性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=869698, createdName=ligang4439, createdTime=Sun Dec 09 20:20:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620952, encodeId=e3e2162095247, content=<a href='/topic/show?id=92008691089' target=_blank style='color:#2F92EE;'>#芬戈莫德#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86910, encryptionId=92008691089, topicName=芬戈莫德)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=311d20178410, createdName=shenxlcyp, createdTime=Sun Apr 22 04:20:00 CST 2018, time=2018-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307603, encodeId=237230e6030c, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Fri Apr 20 13:45:36 CST 2018, time=2018-04-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1981199, encodeId=67ea19811992d, content=<a href='/topic/show?id=ccaf4332947' target=_blank style='color:#2F92EE;'>#多灶性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43329, encryptionId=ccaf4332947, topicName=多灶性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a885259, createdName=yourmama, createdTime=Thu Oct 18 02:20:00 CST 2018, time=2018-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700886, encodeId=5c151e0088609, content=<a href='/topic/show?id=5bc99439474' target=_blank style='color:#2F92EE;'>#进行性多灶性白质脑病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94394, encryptionId=5bc99439474, topicName=进行性多灶性白质脑病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c15930270246, createdName=xuyu, createdTime=Mon Dec 17 06:20:00 CST 2018, time=2018-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765715, encodeId=f32b1e65715ae, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Dec 14 15:20:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000398, encodeId=b341200039878, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Oct 10 09:20:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666416, encodeId=9eba1666416ff, content=<a href='/topic/show?id=55c6849451c' target=_blank style='color:#2F92EE;'>#脑病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84945, encryptionId=55c6849451c, topicName=脑病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db0126060584, createdName=showtest, createdTime=Fri Jan 25 23:20:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976609, encodeId=31c019e660932, content=<a href='/topic/show?id=acd4943925f' target=_blank style='color:#2F92EE;'>#进行性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94392, encryptionId=acd4943925f, topicName=进行性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=869698, createdName=ligang4439, createdTime=Sun Dec 09 20:20:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620952, encodeId=e3e2162095247, content=<a href='/topic/show?id=92008691089' target=_blank style='color:#2F92EE;'>#芬戈莫德#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86910, encryptionId=92008691089, topicName=芬戈莫德)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=311d20178410, createdName=shenxlcyp, createdTime=Sun Apr 22 04:20:00 CST 2018, time=2018-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307603, encodeId=237230e6030c, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Fri Apr 20 13:45:36 CST 2018, time=2018-04-20, status=1, ipAttribution=)]
    2018-10-10 yinhl1978
  5. [GetPortalCommentsPageByObjectIdResponse(id=1981199, encodeId=67ea19811992d, content=<a href='/topic/show?id=ccaf4332947' target=_blank style='color:#2F92EE;'>#多灶性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43329, encryptionId=ccaf4332947, topicName=多灶性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a885259, createdName=yourmama, createdTime=Thu Oct 18 02:20:00 CST 2018, time=2018-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700886, encodeId=5c151e0088609, content=<a href='/topic/show?id=5bc99439474' target=_blank style='color:#2F92EE;'>#进行性多灶性白质脑病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94394, encryptionId=5bc99439474, topicName=进行性多灶性白质脑病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c15930270246, createdName=xuyu, createdTime=Mon Dec 17 06:20:00 CST 2018, time=2018-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765715, encodeId=f32b1e65715ae, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Dec 14 15:20:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000398, encodeId=b341200039878, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Oct 10 09:20:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666416, encodeId=9eba1666416ff, content=<a href='/topic/show?id=55c6849451c' target=_blank style='color:#2F92EE;'>#脑病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84945, encryptionId=55c6849451c, topicName=脑病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db0126060584, createdName=showtest, createdTime=Fri Jan 25 23:20:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976609, encodeId=31c019e660932, content=<a href='/topic/show?id=acd4943925f' target=_blank style='color:#2F92EE;'>#进行性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94392, encryptionId=acd4943925f, topicName=进行性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=869698, createdName=ligang4439, createdTime=Sun Dec 09 20:20:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620952, encodeId=e3e2162095247, content=<a href='/topic/show?id=92008691089' target=_blank style='color:#2F92EE;'>#芬戈莫德#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86910, encryptionId=92008691089, topicName=芬戈莫德)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=311d20178410, createdName=shenxlcyp, createdTime=Sun Apr 22 04:20:00 CST 2018, time=2018-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307603, encodeId=237230e6030c, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Fri Apr 20 13:45:36 CST 2018, time=2018-04-20, status=1, ipAttribution=)]
    2019-01-25 showtest
  6. [GetPortalCommentsPageByObjectIdResponse(id=1981199, encodeId=67ea19811992d, content=<a href='/topic/show?id=ccaf4332947' target=_blank style='color:#2F92EE;'>#多灶性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43329, encryptionId=ccaf4332947, topicName=多灶性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a885259, createdName=yourmama, createdTime=Thu Oct 18 02:20:00 CST 2018, time=2018-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700886, encodeId=5c151e0088609, content=<a href='/topic/show?id=5bc99439474' target=_blank style='color:#2F92EE;'>#进行性多灶性白质脑病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94394, encryptionId=5bc99439474, topicName=进行性多灶性白质脑病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c15930270246, createdName=xuyu, createdTime=Mon Dec 17 06:20:00 CST 2018, time=2018-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765715, encodeId=f32b1e65715ae, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Dec 14 15:20:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000398, encodeId=b341200039878, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Oct 10 09:20:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666416, encodeId=9eba1666416ff, content=<a href='/topic/show?id=55c6849451c' target=_blank style='color:#2F92EE;'>#脑病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84945, encryptionId=55c6849451c, topicName=脑病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db0126060584, createdName=showtest, createdTime=Fri Jan 25 23:20:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976609, encodeId=31c019e660932, content=<a href='/topic/show?id=acd4943925f' target=_blank style='color:#2F92EE;'>#进行性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94392, encryptionId=acd4943925f, topicName=进行性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=869698, createdName=ligang4439, createdTime=Sun Dec 09 20:20:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620952, encodeId=e3e2162095247, content=<a href='/topic/show?id=92008691089' target=_blank style='color:#2F92EE;'>#芬戈莫德#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86910, encryptionId=92008691089, topicName=芬戈莫德)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=311d20178410, createdName=shenxlcyp, createdTime=Sun Apr 22 04:20:00 CST 2018, time=2018-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307603, encodeId=237230e6030c, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Fri Apr 20 13:45:36 CST 2018, time=2018-04-20, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1981199, encodeId=67ea19811992d, content=<a href='/topic/show?id=ccaf4332947' target=_blank style='color:#2F92EE;'>#多灶性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43329, encryptionId=ccaf4332947, topicName=多灶性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a885259, createdName=yourmama, createdTime=Thu Oct 18 02:20:00 CST 2018, time=2018-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700886, encodeId=5c151e0088609, content=<a href='/topic/show?id=5bc99439474' target=_blank style='color:#2F92EE;'>#进行性多灶性白质脑病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94394, encryptionId=5bc99439474, topicName=进行性多灶性白质脑病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c15930270246, createdName=xuyu, createdTime=Mon Dec 17 06:20:00 CST 2018, time=2018-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765715, encodeId=f32b1e65715ae, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Dec 14 15:20:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000398, encodeId=b341200039878, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Oct 10 09:20:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666416, encodeId=9eba1666416ff, content=<a href='/topic/show?id=55c6849451c' target=_blank style='color:#2F92EE;'>#脑病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84945, encryptionId=55c6849451c, topicName=脑病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db0126060584, createdName=showtest, createdTime=Fri Jan 25 23:20:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976609, encodeId=31c019e660932, content=<a href='/topic/show?id=acd4943925f' target=_blank style='color:#2F92EE;'>#进行性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94392, encryptionId=acd4943925f, topicName=进行性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=869698, createdName=ligang4439, createdTime=Sun Dec 09 20:20:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620952, encodeId=e3e2162095247, content=<a href='/topic/show?id=92008691089' target=_blank style='color:#2F92EE;'>#芬戈莫德#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86910, encryptionId=92008691089, topicName=芬戈莫德)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=311d20178410, createdName=shenxlcyp, createdTime=Sun Apr 22 04:20:00 CST 2018, time=2018-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307603, encodeId=237230e6030c, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Fri Apr 20 13:45:36 CST 2018, time=2018-04-20, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1981199, encodeId=67ea19811992d, content=<a href='/topic/show?id=ccaf4332947' target=_blank style='color:#2F92EE;'>#多灶性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43329, encryptionId=ccaf4332947, topicName=多灶性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a885259, createdName=yourmama, createdTime=Thu Oct 18 02:20:00 CST 2018, time=2018-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700886, encodeId=5c151e0088609, content=<a href='/topic/show?id=5bc99439474' target=_blank style='color:#2F92EE;'>#进行性多灶性白质脑病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94394, encryptionId=5bc99439474, topicName=进行性多灶性白质脑病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c15930270246, createdName=xuyu, createdTime=Mon Dec 17 06:20:00 CST 2018, time=2018-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765715, encodeId=f32b1e65715ae, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Dec 14 15:20:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000398, encodeId=b341200039878, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Oct 10 09:20:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666416, encodeId=9eba1666416ff, content=<a href='/topic/show?id=55c6849451c' target=_blank style='color:#2F92EE;'>#脑病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84945, encryptionId=55c6849451c, topicName=脑病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db0126060584, createdName=showtest, createdTime=Fri Jan 25 23:20:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976609, encodeId=31c019e660932, content=<a href='/topic/show?id=acd4943925f' target=_blank style='color:#2F92EE;'>#进行性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94392, encryptionId=acd4943925f, topicName=进行性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=869698, createdName=ligang4439, createdTime=Sun Dec 09 20:20:00 CST 2018, time=2018-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620952, encodeId=e3e2162095247, content=<a href='/topic/show?id=92008691089' target=_blank style='color:#2F92EE;'>#芬戈莫德#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86910, encryptionId=92008691089, topicName=芬戈莫德)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=311d20178410, createdName=shenxlcyp, createdTime=Sun Apr 22 04:20:00 CST 2018, time=2018-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307603, encodeId=237230e6030c, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Fri Apr 20 13:45:36 CST 2018, time=2018-04-20, status=1, ipAttribution=)]
    2018-04-20 惠映实验室

    学习了.谢谢分享.

    0

相关资讯

Neurology:芬戈莫德治疗多发性硬化可增黄斑体积

  研究表明:MS患者接受芬戈莫德治疗与中等程度、相对快速的黄斑容积增加相关。   芬戈莫德是一种鞘氨醇-1-磷酸受体调节剂,是首个口服治疗多发性硬化的药物,在2010年获FDA批准用于多发性硬化的治疗,商品名Gilenya。为了研究芬戈莫德能否在总体上带来视网膜组织体积的增加,美国加州大学旧金山分校神经科多发性硬化研究中心的Rachel Nolan学士等人员进行了一项研究,研究结果发

Cancer Cell:芬戈莫德或可用于结直肠癌

 弗吉尼亚联邦大学梅西癌症中心的科学家在发现可诱发慢性肠道炎症和促进结直肠癌恶化的相关机制之后,近日又通过研究发现,用于治疗多发性硬化症的药物芬戈莫德或能削弱和消除结肠炎相关癌症(CAC)的发展。   这项发表在《癌细胞》杂志网页版上的研究是由梅西癌症中心的Sarah Spiegel博士领导进行的。Speigel博士的研究团队发现,鞘氨醇激酶1(SphK1)分泌增加会导致肠道内膜细

Nat Neurosci:芬戈莫德或可帮助忘记疼痛

许多人在发生车祸或严重外伤后,会受到“创伤后应激障碍”的困扰。一项最新研究发现,一种治疗多发性硬化症的药物或许可以帮助减轻这种创伤记忆。 这种药物名为芬戈莫德,它含有的一种小分子可以对人体免疫系统产生一定的抑制作用,有助于多发性硬化症患者体内免疫系统的调节,缓解因免疫系统过度活跃造成的一系列炎症等症状。 美国研究人员在新一期英国《自然-神经学》杂志上报告说,他们通过动物实验首次发现芬戈莫德具有

FDA评估多发性硬化新药Gilenya心血管安全性

       2012年5月14日,美国食品药品管理局(FDA)宣布,已评估了1例患者使用首剂多发性硬化治疗药Gilenya(芬戈莫德)后死亡的报告。该机构还评估了Gilenya临床试验和上市后的其他数据,包括死于心血管事件或死因不明患者的报告。目前,FDA还不能确定使用Gilenya是否与这些死亡有关。   &

JAMA Neurol:对复发型多发性硬化芬戈莫德优于传统的注射免疫调节剂

正在接受注射用疾病调节剂治疗的的多发性硬化患者复发后,众多医生都会倾向于转换药物。怎么转换?不同转换药物疗法的疗效如何常常不甚明确。芬戈莫德是一个有效的药物,但是从其他治疗方案里换药到芬戈莫德效果又如何呢?为比较MS复发或者疾病进展后转换药物使用口服免疫调节药芬戈莫德和仍使用注射用免疫调节剂(干扰素或者醋酸格拉默)治疗后两种治疗方案下的复发率,残疾情况,治疗耐受性情况,研究者开展此实验。研究者将来